Dianthus Therapeutics (NASDAQ:DNTH) Stock Keeps “Buy” Rating at HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $158.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 112.00% from the stock’s current price.

A number of other research firms have also recently commented on DNTH. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Truist Financial upped their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Citigroup initiated coverage on Dianthus Therapeutics in a research note on Friday, September 4th. They set a “buy” rating and a $156.00 price target on the stock. Raymond James Financial reissued a “strong-buy” rating and set a $131.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They issued an “overweight” rating and a $135.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $129.83.

Dianthus Therapeutics Stock Down 0.3%

Shares of Dianthus Therapeutics stock opened at $74.53 on Thursday. Dianthus Therapeutics has a 52 week low of $32.22 and a 52 week high of $117.88. The firm’s 50 day moving average is $100.04 and its two-hundred day moving average is $94.44. The firm has a market capitalization of $4.08 billion, a P/E ratio of -17.96 and a beta of 1.35.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, research analysts expect that Dianthus Therapeutics will post -3.81 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Anne McGeorge sold 7,750 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $109.01, for a total transaction of $844,827.50. Following the sale, the director owned 1,250 shares in the company, valued at $136,262.50. This trade represents a 86.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Edward Carr sold 20,000 shares of Dianthus Therapeutics stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the completion of the sale, the chief accounting officer directly owned 20,000 shares of the company’s stock, valued at approximately $2,027,600. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 242,429 shares of company stock valued at $26,118,913 in the last 90 days. Insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Walleye Capital LLC purchased a new stake in Dianthus Therapeutics in the second quarter valued at approximately $1,743,000. SummitTX Capital L.P. grew its position in Dianthus Therapeutics by 13.8% during the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock valued at $8,396,000 after acquiring an additional 12,118 shares during the period. California State Teachers Retirement System grew its position in Dianthus Therapeutics by 155.5% during the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after acquiring an additional 24,697 shares during the period. Bank of America Corp DE acquired a new stake in Dianthus Therapeutics during the second quarter worth about $25,036,000. Finally, Spruce Street Capital LP purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter worth about $34,587,464. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.